Elanco Scales Biologics Capabilities With Expansion of Kansas Manufacturing Facility

The completed 25,000-square-foot Elwood site expansion bolsters Elanco's monoclonal antibody (mAb) production; supports delivery of next-generation pipeline

INDIANAPOLIS, IN / ACCESS Newswire / August 31, 2026 / Elanco Animal Health Incorporated (NYSE:ELAN) announced the on-time completion of a 25,000-square-foot manufacturing expansion of its Elwood, Kansas manufacturing site. As one of only two animal health companies with mAb solutions on the market today, the expansion further strengthens Elanco's leadership in the biologics space.